By Fineline Cube 
Star Sports Medicine Co., Ltd., a Chinese sports medical device manufacturer, successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, issuing 8,421,850 shares at HKD 98.5 (USD 12.57) per share. The listing raised HKD 830 million (USD 105.9 million), positioning the company for expanded market leadership in China’s growing sports medicine sector.
IPO Transaction Details
| Item | Detail |
|---|---|
| Company | Star Sports Medicine Co., Ltd. |
| Exchange | Hong Kong Stock Exchange |
| Shares Offered | 8,421,850 |
| Offering Price | HKD 98.5 per share (USD 12.57) |
| Gross Proceeds | HKD 830 million (USD 105.9 million) |
| Transaction Week | Week of April 24, 2026 |
Product Portfolio & Therapeutic Focus
Comprehensive Sports Medicine Solutions
- Implants: Self-developed orthopedic implants for soft tissue repair
- Active Devices: Advanced therapeutic and diagnostic equipment
- Consumables: Procedure-specific disposable products
- Surgical Instruments: Specialized tools for minimally invasive procedures
Anatomical Coverage
The company provides treatments for soft tissue injuries across multiple joints:
- Shoulder: Rotator cuff repairs
- Knee: Ligament and meniscus reconstruction
- Hip: Soft tissue stabilization procedures
- Foot/Ankle: Ligament and tendon repairs
- Elbow: Tendon and ligament reconstruction
- Hand/Wrist: Microsurgical soft tissue procedures
Integrated Care Model
- Treatment: Comprehensive surgical solutions for acute and chronic sports injuries
- Rehabilitation: Post-operative recovery protocols and equipment
- Prevention: Prophylactic solutions and injury prevention programs
Market Position & Competitive Landscape
Leadership Metrics
- Market Rank: Fourth largest provider of sports medicine implants and instruments in China
- Market Share: Approximately 6.5% of China’s sports medicine implant and instrument market
- Domestic Leadership: Largest domestic provider of sports medicine implants and instruments
- Competitive Advantage: Vertically integrated product development and manufacturing capabilities
Strategic Significance
The IPO capital will support:
- Expansion of R&D capabilities for next-generation sports medicine technologies
- Enhancement of manufacturing capacity to meet growing domestic demand
- International market exploration opportunities
- Strengthening of distribution network across China’s tier-1 and tier-2 cities
China’s sports medicine market is experiencing robust growth driven by increasing sports participation, aging population with active lifestyles, and rising healthcare expenditure. Star Sports Medicine’s position as the leading domestic player provides strategic advantages in regulatory navigation, physician relationships, and cost-effective innovation.
Forward‑Looking Statements
This brief contains forward-looking statements regarding IPO proceeds utilization, market expansion, and competitive positioning. Actual financial performance, market share evolution, and international expansion timelines may differ based on regulatory approvals, competitive dynamics, and macroeconomic conditions.-Fineline Info & Tech